Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities

Menter, Alan; Krueger, Gerald G.; Paek, So Yeon; Kivelevitch, Darío; Adamopoulos, Iannis E.; Langley, Richard

doi:10.1007/s13555-021-00483-2

Cited by 41 publications

(41 citation statements)

References 143 publications

(101 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarities exist between the immunopathologies of psoriasis, atherosclerosis and metabolic syndrome. This includes promoting the differentiation of Th1 and Th17 cells and the secretion of pro-inflammatory cytokines such as TNF-α, IFN-γ, IL-17A and IL-22 [ 31 ]. In atherosclerosis, IL-17 and TNF-α synergistically activate NF-κB signaling and mitogen-activated protein kinases to induce neutrophil-attracting chemokines and other inflammation modulators, and increase aortic inflammation and thrombosis, eventually exacerbating cardiovascular diseases and increasing the morbidity associated with them [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

“…This includes promoting the differentiation of Th1 and Th17 cells and the secretion of pro-inflammatory cytokines such as TNF-α, IFN-γ, IL-17A and IL-22 [31]. In atherosclerosis, IL-17 and TNF-α synergistically activate NF-κB signaling and mitogen-activated protein kinases to induce neutrophil-attracting chemokines and other inflammation modulators, and increase aortic inflammation and thrombosis, eventually exacerbating cardiovascular diseases and increasing the morbidity associated with them [31]. The neutralization of IL-17 lead to a significant improvement in patients with psoriasis or ankylosing spondylitis including lasso cardiovascular comorbidities [32,33] Bertol et al found that the expression of IL-17A in the vascular fraction of the adipose tissue stroma was higher in overweight and obese patients compared to the control group with a normal body weight, contrary to the earlier opinion that IL-17A counteracts adipogenesis [34].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

IL-17A, IL-17E and IL-17F as Potential Biomarkers for the Intensity of Low-Grade Inflammation and the Risk of Cardiovascular Diseases in Obese People

Polak-Szczybyło

Tabarkiewicz

2022

Nutrients

View full text Add to dashboard Cite

Low-grade inflammation is a factor that predisposes to many obesity-related comorbidities. The immune mechanisms controlling the inflammatory response related to the secretory activity of adipocytes and its consequences for the organism are still under investigation. Methods: 84 obese adult volunteers (BMI ≥ 30 kg/m2) were tested by BIA. Serum samples were collected to analyze the concentrations of interleukins IL-17A, IL-17E and IL-17F. The subjects completed the original questionnaire, the FFQ-6 food consumption frequency questionnaire and the food diary. Results: The level of IL-17E and IL-17F was positively correlated with the BMI value and the level of IL-17E increased with the content of subcutaneous fat. Its increased blood concentration was also observed in individuals who declared that they were diagnosed with atherosclerosis and/or were taking beta-blockers. Products that were related with a low level of the above-mentioned interleukins were vegetables, groats, eggs, red meat, fast-food and alcohol. The level of these interleukins was positively correlated with the frequent consumption of confectionery and breakfast cereals. Nutrients that decreased the concentrations of IL-17 isoforms were potassium, iron, vitamins B6 and C, and folic acid. Conclusions: Both IL-17E and IL-17F may be closely related to the intensity of low-grade inflammation and be biomarkers of cardiovascular disease risk. Food products or the nutrients they contain may affect the levels of the above-mentioned interleukins as well as IL-17A.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

IL-17A, IL-17E and IL-17F as Potential Biomarkers for the Intensity of Low-Grade Inflammation and the Risk of Cardiovascular Diseases in Obese People

Polak-Szczybyło

Tabarkiewicz

2022

Nutrients

View full text Add to dashboard Cite

show abstract

“…Currently, it is acknowledged that these disorders share a link with chronic inflammation based on the activation of myeloid DCs and endothelial cells, promoting differentiation of Th1 and Th17 cells and secretion of pro-inflammatory cytokines such as TNF-α, IFN-γ, IL-17A, and IL-22, via activation of NF-κB and MAPK signaling [62].…”

Section: Il-17 Isoforms Beyond Psoriasismentioning

confidence: 99%

From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment

Vidal

Puig

Carrascosa-Carrillo

et al. 2021

IJMS

View full text Add to dashboard Cite

The paradigm of psoriasis as a Th17-driven disease has evolved in the last years towards a much deeper knowledge of the complex pathways, mechanisms, cells, and messengers involved, highlighting the crucial role played by the IL-17 family of cytokines. All IL-17 isoforms signal through IL-17R. Five subunits of IL-17R have been described to date, which couple to form a homo- or hetero-receptor complex. Characteristically, IL-17RA is a common subunit in all hetero-receptors. IL-17RA has unique structural—containing a SEFIR/TILL domain—and functional—requiring ACT-1 for signaling—properties, enabling Th17 cells to act as a bridge between innate and adaptive immune cells. In psoriasis, IL-17RA plays a key role in pathogenesis based on: (a) IL-17A, IL-17F, and other IL-17 isoforms are involved in disease development; and (b) IL-17RA is essential for signaling of all IL-17 cytokines but IL-17D, whose receptor has not been identified to date. This article reviews current evidence on the biology and role of the IL-17 family of cytokines and receptors, with focus on IL-17RA, in psoriasis and some related comorbidities, and puts them in context with current and upcoming treatments.

show abstract

“…Noteworthy is that it stimulates the proliferation and differentiation of T lymphocytes, Th1, Th17, and Th22, which in turn will produce TNF-α, IL-17, IL-22, favoring initiation of a self-propelled cycle of inflammation. Essentially, this cytokine plays an indirect role in disease pathogenesis by promoting adaptive immune effects of the IL-23/IL-17 axis [ 29 , 30 , 31 , 32 , 33 ].…”

Section: Resultsmentioning

confidence: 99%

Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches

et al. 2021

View full text Add to dashboard Cite

Psoriasis is an immune-mediated inflammatory disease, with a chronic relapsing-remitting course, which affects 2–3% of the worldwide population. The progressive acquisitions of the inflammatory pathways involved in the development of psoriasis have led to the identification of the key molecules of the psoriatic inflammatory cascade. At the same time, psoriasis therapy has radically evolved with the introduction of target molecules able to modify the natural history of the disease, acting specifically on these inflammatory pathways. For these reasons, biologics have been demonstrated to be drugs able to change the disease’s natural history, as they reduce the inflammatory background to avoid irreversible organ damage and prevent systemic complications. However, several issues related to the use of biologics in patients with systemic comorbidities, remain open. All these data reflect the extraordinary potentiality of biologics, but also the unmet medical need to improve our knowledge on the long-term risk related to continuous use of these drugs, and their administration in special populations. This narrative review aims to highlight both the efficacy and safety profile of biologics in psoriasis, starting from pathophysiology and moving towards their clinical application.

show abstract

Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities

Cited by 41 publications

References 143 publications

IL-17A, IL-17E and IL-17F as Potential Biomarkers for the Intensity of Low-Grade Inflammation and the Risk of Cardiovascular Diseases in Obese People

IL-17A, IL-17E and IL-17F as Potential Biomarkers for the Intensity of Low-Grade Inflammation and the Risk of Cardiovascular Diseases in Obese People

From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment

Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches

Contact Info

Product

Resources

About